Law & Regulation
DEA psychedelics ban hearing halted by lawsuit
The firm is arguing the DEA’s administrative rulemaking process has been unlawful and would hamper its research efforts.
The post DEA psychedelics ban…
A Drug Enforcement Administration judge has postponed a June hearing on the agency’s proposal to ban two psychedelic substances after a pharmaceutical company filed a federal lawsuit challenging the move, according to court documents released Thursday.
Administrative Law Judge Paul Soeffing ordered the DEA to cancel the June 10 hearing while Panacea Plant Sciences’ lawsuit plays out in U.S. District Court in Seattle, Law360 reported. The Washington-based company is seeking to halt the regulatory proceedings.
In December, the DEA initiated a proposed rulemaking process to classify the hallucinogens 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I controlled substances, the most restrictive category under federal law.
Panacea, which is researching the substances’ potential therapeutic benefits, filed the lawsuit last month, arguing the DEA’s administrative rulemaking process has been unlawful and would hamper its research efforts.
“Although the public interest may lie in an expeditious and efficient resolution to these proceedings, the public interest also lies in ensuring parties are not potentially subjected to an adjudication process found unconstitutional,” Judge Soeffing said in his decision.
The judge directed the DEA to publish a notice informing the public that the June hearing is canceled and proceedings are stayed pending the lawsuit’s resolution. As of Thursday, no notice had been published in the Federal Register.
“Panacea Plant Sciences is thankful the (administrative law judge) agreed in the need for a stay,” CEO David Heldreth said in an email to the outlet. “We look forward to DEA publishing the ordered notice to alert the public to the cancelation of the hearing.”
The company’s lawsuit seeks an injunction halting the regulatory proceedings and a declaration that the DEA’s process has been unlawful. Panacea alleges moving the drugs to Schedule I would critically hamper its research into their potential uses for treating asthma, pain, and inflammation.
1835000-1835534-scheduling of doi and doc_order granting panacea second motion to stayThe post DEA psychedelics ban hearing halted by lawsuit appeared first on Green Market Report.
research psychedelics psychedelic
-
Law & Regulation1 week agoRelmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics6 days agoBetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics5 days agoatai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation7 days agoAbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics6 days agoSilo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
-
Psychedelics6 days agoCybin to Participate in the Alliance Global Partners Healthcare Company Showcase
-
Law & Regulation5 days ago
FDA nod fuels Filament’s psychedelics push, but cash running short
-
Psychedelics6 days agoOptimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
